查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2105176

皮膚燒傷市場：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

Global Skin Burn - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 156 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國燒傷治療市場預計將從 2025 年的 5,000 萬美元成長到 2035 年的 8,500 萬美元。
  • 以下因素正在推動市場成長：
  • 擴大先進創傷護理和皮膚修復療法的應用。
  • 生物製藥和組織工程產品的持續創新
  • 未來的發展取決於能夠改善治療效果並減少長期併發症的療法。

皮膚燒傷概述

皮膚燒傷是由熱、化學物質、電或輻射引起的損傷，其嚴重程度從表皮損傷到無法自行癒合的全層皮膚損傷不等。傳統上，大面積燒傷採用自體皮膚移植治療，但這種方法受限於健康捐贈者皮膚的來源。這促使人們開發人工皮膚替代物和細胞療法，這些療法能夠增殖患者自身的皮膚細胞或提供臨時生物覆蓋物，以促進癒合和減少疤痕。更先進的再生醫學方法，包括3D生物列印，正在研究中，其目標不僅是替代受損組織，還要再生功能性皮膚。一些醫療保險計劃中針對先進皮膚替代物的報銷政策近期發生變化，也影響這些療法的提供地點和方式。對於相關人員而言，燒傷治療是臨床創新和保險報銷政策如何共同影響患者獲得先進治療的典型例子。

主要亮點

  • 根據預測，德國新增皮膚燒傷病例數將從 2025 年的 319,485 例增加到 2035 年的 325,306 例。
  • 皮膚燒傷仍然是住院、長期殘疾和醫療負擔的主要原因。
  • 嚴重燒傷需要專門的創傷護理，以減少併發症並促進癒合。
  • 目前，對於能夠促進創傷治療和最大限度減少疤痕的先進治療方法，仍存在巨大的未滿足需求。

市場定義：

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

目錄

第1章：主要調查結果和分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法－概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

  • 尚未滿足的主要需求及其透過新興療法實現的潛力。
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Global Skin Burn Market Outlook

Thelansis's "Global Skin Burn Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Skin Burn treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Skin Burn Overview

A skin burn is an injury caused by heat, chemicals, electricity, or radiation that can range from superficial damage to full-thickness wounds incapable of healing without intervention. Extensive burns have traditionally been treated with autologous skin grafting, but this approach is limited by the availability of healthy donor skin. This has driven the development of engineered skin substitutes and cell-based therapies that expand a patient's own skin cells or provide temporary biological coverage to promote healing and reduce scarring. More advanced regenerative approaches, including 3D bioprinting, are being investigated to restore functional skin rather than simply replace lost tissue. In some healthcare systems, recent changes in reimbursement for advanced skin substitutes are also influencing where and how these therapies are delivered. For stakeholders, burn care illustrates how clinical innovation and reimbursement policy together shape patient access to advanced treatments.

Key Highlights

  • In Germany, incident Skin Burn cases are projected to increase from 319,485 in 2025 to 325,306 by 2035.
  • Skin burns remain a major cause of hospitalization, long-term disability, and healthcare burden.
  • Severe burns require specialized wound care to reduce complications and improve recovery.
  • Significant unmet need remains for advanced therapies that accelerate wound healing and minimize scarring.

Market Overview

  • The France Skin Burns market is projected to grow from $50M in 2025 to $85M by 2035.
  • Market growth is driven by:
  • Increasing adoption of advanced wound care and skin regeneration therapies
  • Ongoing innovation in biologics and tissue-engineered products
  • Future growth will depend on therapies that improve healing outcomes and reduce long-term complications.

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)